Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;8(1):121-132.
doi: 10.1007/s40122-019-0112-6. Epub 2019 Jan 16.

Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain

Himanshu D Patel  1 , R B Uppin  2 , A Ramakrishnam Naidu  3 , Y Ratnakar Rao  4 , Suhas Khandarkar  5 , Amit Garg  6
Affiliations

Efficacy and Safety of Combination of NSAIDs and Muscle Relaxants in the Management of Acute Low Back Pain

Himanshu D Patel et al. Pain Ther. 2019 Jun.

Abstract

Introduction: Low back pain is a common problem worldwide causing deterioration of health and quality of life. Low back pain is often associated with muscle spasm. We investigated the combined effect of muscle relaxants and pain killers for low back pain.

Methods: In this open-label, prospective, multicenter study, patients with acute low back pain received a single tablet of either the fixed dose combination of chlorzoxazone 500 mg and ibuprofen 400 mg (manufacturer: Dr. Reddy's Laboratories, India) (C + I group) or ibuprofen 400 mg (I group) thrice daily for up to 7 days. Primary outcomes were improvement in pain by Visual Analogue Scale (VAS) and Summed Pain Intensity Difference (SPID) at 3 and 7 days post-treatment.

Results: A total of 406 patients were included in this study. When compared to baseline, the absolute mean change in VAS scores on Day 7 was 62.39 ± 18.78 and 57.34 ± 16.29 in the C + I and I groups, respectively (P = 0.0001). In the C + I and I groups, the mean SPID at Days 3 and 7 were 51.27 ± 24.44 and 47.80 ± 22.91, and 300.82 ± 92.40 and 277.16 ± 81.83, respectively. No deaths or serious adverse events were reported. Common adverse events included gastritis, stomach pain, fever, cold, and headache. At the end of the study, excellent to good response was reported in 94.08% and 77.33% of patients in the C + I and I groups, respectively. Excellent to good tolerability was observed in 96.05% and 89.65% patients in the two groups, respectively.

Conclusion: Fixed dose combination of chlorzoxazone and ibuprofen demonstrated superior efficacy than ibuprofen monotherapy in acute low back pain. Both drugs were well-tolerated and should be considered as judicious therapeutic options in patients with acute low back pain.

Trial registration: This trial is registered with Clinical Trial Registry of India-CTRI/2016/10/007348.

Funding: Dr. Reddy's Laboratories Ltd.

Keywords: Anti-inflammatory agents; Chlorzoxazone; Ibuprofen; Low back pain; Non-steroidal; Spasm.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Visual analogue score during movement at baseline and Days 3 and 7
Fig. 2
Fig. 2
Mean of total pain relief scores after treatment administration
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Patrick N, Emanski E, Knaub MA. Acute and chronic low back pain. Med Clin N Am. 2014;98:777–789. - PubMed
    1. May S. Self-management of chronic low back pain and osteoarthritis. Nat Rev Rheumatol. 2010;6(4):199–209. - PubMed
    1. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008;8(1):8–20. - PubMed
    1. Frydrych V. Skeletal Muscle Relaxants. Drug Class Review. 2016. https://medicaid.utah.gov/pharmacy/ptcommittee/files/Criteria%20Review%2.... Accessed on: 01 Oct, 2018.
    1. Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166:480–492. - PubMed

LinkOut - more resources